Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnWeb3SquareMore
Trade
Spot
Buy and sell crypto with ease
Margin
Amplify your capital and maximize fund efficiency
Onchain
Going Onchain, without going Onchain!
Convert & block trade
Convert crypto with one click and zero fees
Explore
Launchhub
Gain the edge early and start winning
Copy
Copy elite trader with one click
Bots
Simple, fast, and reliable AI trading bot
Trade
USDT-M Futures
Futures settled in USDT
USDC-M Futures
Futures settled in USDC
Coin-M Futures
Futures settled in cryptocurrencies
Explore
Futures guide
A beginner-to-advanced journey in futures trading
Futures promotions
Generous rewards await
Overview
A variety of products to grow your assets
Simple Earn
Deposit and withdraw anytime to earn flexible returns with zero risk
On-chain Earn
Earn profits daily without risking principal
Structured Earn
Robust financial innovation to navigate market swings
VIP and Wealth Management
Premium services for smart wealth management
Loans
Flexible borrowing with high fund security
Combating Obesity: Trump’s Pharmaceutical Agreement Cuts Costs for Millions

Combating Obesity: Trump’s Pharmaceutical Agreement Cuts Costs for Millions

Bitget-RWA2025/11/06 23:50
By:Bitget-RWA

- Trump administration secures $350-$149/month price cuts for GLP-1 drugs via TrumpRx.gov, expanding Medicare/Medicaid coverage to 40% of obese Americans. - Lilly and Novo Nordisk commit to aligning U.S. pricing with global benchmarks under MFN framework, part of broader cost-control measures including FDA incentives. - Policy faces $35B annual deficit risks from high demand, while pharma firms gain tariff certainty and access to 60M+ beneficiaries previously excluded. - Market reacts cautiously as Novo sh

President Donald Trump has announced a major deal with leading pharmaceutical companies

and to significantly lower the prices of widely used diabetes and weight-loss medications, signaling a major change in Medicare and Medicaid drug coverage. The agreement, revealed on November 6, will bring down the monthly cost of GLP-1 drugs such as Ozempic and Wegovy to $350 and $149, respectively, for those paying out of pocket and for beneficiaries using the upcoming TrumpRx.gov platform, which is scheduled to go live in January 2026, according to . Individuals covered by Medicare and Medicaid will also be able to obtain these drugs for $245 per month, with a $50 co-payment for beneficiaries, as noted. This initiative will extend access to millions across the country, especially older adults and those with lower incomes, since Medicare had previously not included weight-loss medications in its list of covered drugs, according to .

The administration highlighted that the deal requires

and Novo Nordisk to match U.S. drug prices with those in other countries, following the Most Favored Nation (MFN) pricing model, as reported by . This move is part of Trump’s larger plan to lower drug costs, which also includes possible heavy tariffs on pharmaceutical companies and offering expedited FDA review vouchers for innovative treatments, according to . The price reductions—reaching up to 74% for those paying cash—come after the Centers for Medicare and Medicaid Services (CMS) recently indicated a willingness to include weight-loss drugs in Part D plans, provided they are used for approved medical conditions like diabetes or to reduce cardiovascular risks, as Fortune reported.

The financial impact of this policy is considerable. While the administration has pointed to patient savings, some critics caution that the broader coverage could add $35 billion per year to the national deficit due to the high demand for GLP-1 drugs, Fortune reported. CMS Administrator Mehmet Oz mentioned ongoing talks in October, highlighting the challenge of keeping treatments affordable while maintaining fiscal responsibility. At the same time, pharmaceutical firms gained certain assurances, such as stable tariffs and broader access for patients with obesity—a group that Medicare had previously not covered, according to Morningstar.

The agreements also cover additional medications beyond GLP-1 drugs. Lilly’s Zepbound and Novo’s oral Wegovy will be available for $346 and $150 per month, respectively, and insulin products will be priced at $35 per month through TrumpRx, as reported by Investors Business Daily. The companies are also investing further in U.S. manufacturing, with Lilly committing $27 billion and Novo $10 billion, according to Yahoo Finance. The market response was mixed: Novo Nordisk’s stock dropped by 3.5%, while Lilly’s saw a slight decline, reflecting investor uncertainty amid increased regulatory scrutiny, Investors Business Daily reported.

This policy change addresses a significant public health issue, as the CDC reports that 40% of American adults are obese, according to Investors Business Daily. By including weight-loss medications in Medicare, the Trump administration seeks to tackle chronic illnesses associated with obesity, such as diabetes and heart disease, while also working to lower prescription costs. However, the long-term effectiveness of this approach will depend on controlling Medicare expenses and ensuring all eligible patients have fair access, Axios reported.

0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!

You may also like

Fed Backs Stablecoins While Regulations Lag Behind

- Federal Reserve officials highlight stablecoins as a transformative force in global payments, emphasizing cost reduction and cross-border efficiency. - Latin America's 60%+ crypto users adopt stablecoins like USDT to hedge against currency devaluation, with Brazil classifying them as formal assets. - U.S. banks and tech firms (PayPal, JPMorgan) leverage stablecoins for 24/7 settlements and low-fee transactions, accelerated by the GENIUS Act. - Regulatory challenges persist as bipartisan crypto legislatio

Bitget-RWA2025/11/07 01:58
Fed Backs Stablecoins While Regulations Lag Behind

DeFi’s Fragile Foundation: USDX Crash Highlights Weaknesses in Synthetic Stablecoins

- USDX stablecoin, issued by Stable Labs, has plunged to $0.74 due to a Balancer V2 Vault exploit draining $100M, triggering forced liquidations and depegging from $1. - The collapse exposed vulnerabilities in synthetic stablecoin mechanisms, with inactive collateral rebalancing and cross-collateral swaps exacerbating liquidity crises across DeFi platforms. - Emergency governance actions (e.g., Lista DAO's LIP 022) aim to curb losses via oracle price adjustments, while experts warn of systemic risks in int

Bitget-RWA2025/11/07 01:58
DeFi’s Fragile Foundation: USDX Crash Highlights Weaknesses in Synthetic Stablecoins

Kura Sushi (KRUS) Q4 2025 Earnings Surpass Expectations, Revenue Grows 20.3% Compared to Last Year

- Kura Sushi (KRUS) reported Q4 2025 revenue of $79.4M, up 20.3% YoY, with $0.18 EPS exceeding forecasts. - Net income turned positive at $2. 3M vs. $5.2M loss in 2024, driven by cost cuts and 15 new U.S. locations. - 2026 guidance targets $330-334M sales with 16 new restaurants, but faces challenges in boosting traffic and pricing.

Bitget-RWA2025/11/07 01:58

Ethereum News Update: The Risks of Leverage Revealed—$1.2 Billion in Major Investor Losses Highlight Market Vulnerability

- A top crypto whale's 100% win streak ended with $19.63M loss on BTC/ETH longs, exposing leverage risks in volatile markets. - High-leverage strategies backfired as $1.2B in whale positions liquidated, with longs accounting for 91% of losses. - Ethereum's 9% drop and Bitcoin's 4.63% decline highlight fragility, as whales adjust positions amid shifting liquidity. - Analysts warn whale behavior reflects investor uncertainty, with some doubling down on leveraged bets despite $31M+ monthly losses. - The crisi

Bitget-RWA2025/11/07 01:44
Ethereum News Update: The Risks of Leverage Revealed—$1.2 Billion in Major Investor Losses Highlight Market Vulnerability